Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bevacizumab (a monoclonal antibody targeting VEGF), cyclophosphamide and doxorubicin (often given together as "AC" regimen), and nab-paclitaxel (a nanoparticle albumin-bound formulation of paclitaxel). This regimen has been studied primarily as neoadjuvant therapy for locally advanced breast cancer and inflammatory breast cancer, with clinical trials showing improved pathologic complete response rates, particularly in triple-negative breast cancer.
02
Targets
TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cyclophosphamide + doxorubicin + nab-paclitaxel.